Enabling the Autonomic Management of Federated Identity Providers

The autonomic management of federated authorization infrastructures (federations) is seen as a means for improving the monitoring and use of a service provider’s resources. However, federations are comprised of independent management domains with varying scopes of control and data ownership. The focus of this paper is on the autonomic management of federated identity providers by service providers located in other domains, when the identity providers have been diagnosed as the source of abuse. In particular, we describe how an autonomic controller, external to the domain of the identity provider, exercises control over the issuing of privilege attributes. The paper presents a conceptual design and implementation of an effector for an identity provider that is capable of enabling cross-domain autonomic management. The implementation of an effector for a SimpleSAMLphp identity provider is evaluated by demonstrating how an autonomic controller, together with the effector, is capable of responding to malicious abuse

Impact of glycaemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus

Topics: Basic science, translational and clinical researchPoster PresentationThis journal supplement contains abstracts from the 17th MRC; Dept. of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong KongINTRODUCTION: Patients with type 2 diabetes mellitus (DM) have increased risk of endothelial dysfunction and arterial stiffness. Levels of circulating endothelial progenitor cells (EPCs) are also reduced in hyperglycaemic states. However, the relationships between glycaemic control, levels of EPCs and arterial stiffness are unknown. METHODS: We measured circulating EPCs and …published_or_final_versionThe 17th Medical Research Conference (MRC), Department of Medicine, University of Hong Kong, Hong Kong, 14 January 2012. In Hong Kong Medical Journal, 2012, v. 18 suppl. 1, p. 63, abstract no. 10

One-year clinical outcomes of patients implanted with a Resolute Onyx™ zotarolimus-eluting stent

published_or_final_versio

Split-Drain Magnetic Field-Effect Transistor Channel Charge Trapping and Stress Induced Sensitivity Deterioration

Session EB: Materials for ApplicationsThis paper proposed an analytical model on the deterioration of magnetic sensitivity of sectorial split-drain magnetic field-effect transistors (SD-MAGFETs). The deterioration is governed by the trap fill rate at the channel boundary traps, which is geometric dependent. Experimental results are presented which show good consistency with the analytical derivation. The deterioration is the most severe at a sector angle of 54.6°, which shows a design tradeoff with sensing hysteresis. Design guidelines for sectorial SD-MAGFET to obtain high sensitivity hysteresis and slow sensitivity deterioration are also presented which provide important information for efficient design. © 2013 IEEE.published_or_final_versio

Modified edge-directed interpolation for images

Author name used in this publication: Chi-Wah Kok2009-2010 > Academic research: refereed > Publication in refereed journalVersion of RecordPublishe

Effect of oral health care on Chinese diabetic patients

published_or_final_versio

Social Cognitive Role of Schizophrenia Candidate Gene GABRB2

10.1371/journal.pone.0062322PLoS ONE84

A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac

Alternative-Splicing in the Exon-10 Region of GABAA Receptor β2 Subunit Gene: Relationships between Novel Isoforms and Psychotic Disorders

BACKGROUND: Non-coding single nucleotide polymorphisms (SNPs) in GABRB2, the gene for beta(2)-subunit of gamma-aminobutyric acid type A (GABA(A)) receptor, have been associated with schizophrenia (SCZ) and quantitatively correlated to mRNA expression and alternative splicing. METHODS AND FINDINGS: Expression of the Exon 10 region of GABRB2 from minigene constructs revealed this region to be an "alternative splicing hotspot" that readily gave rise to differently spliced isoforms depending on intron sequences. This led to a search in human brain cDNA libraries, and the discovery of two novel isoforms, beta(2S1) and beta(2S2), bearing variations in the neighborhood of Exon-10. Quantitative real-time PCR analysis of postmortem brain samples showed increased beta(2S1) expression and decreased beta(2S2) expression in both SCZ and bipolar disorder (BPD) compared to controls. Disease-control differences were significantly correlated with SNP rs187269 in BPD males for both beta(2S1) and beta(2S2) expressions, and significantly correlated with SNPs rs2546620 and rs187269 in SCZ males for beta(2S2) expression. Moreover, site-directed mutagenesis indicated that Thr(365), a potential phosphorylation site in Exon-10, played a key role in determining the time profile of the ATP-dependent electrophysiological current run-down. CONCLUSION: This study therefore provided experimental evidence for the importance of non-coding sequences in the Exon-10 region in GABRB2 with respect to beta(2)-subunit splicing diversity and the etiologies of SCZ and BPD

Mind the gap in kidney care: translating what we know into what we do

Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression–kidney failure or death–it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay